In COVID-19 clinical update #94, Daniel Griffin reviews the FDA EUA for Paxlovid, test to stay in school, immunity after infection, variants and therapeutics, quarantine and isolation guidelines, Molnupiravir in non-hospitalized patients, and convalescent serum in outpatients.

Hosts: Daniel Griffin and Vincent Racaniello

Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• FDA EUA for Paxlovid (pdf)
• Children and COVID-19 (pdf)
• Evaluation of test to stay in school, IL (MMWR)
• Evaluation of test to stay in school, LA (MMWR)
• Update on mRNA vaccine in under 5 yo (Pfizer)
• CDC endorses preference for mRNA vaccines (CDC)
• Natural immunity and protection against delta (Clin Inf Dis)
• Cross-neutralization post-vaccination infection (JAMA)
• Variants and therapeutics (NIH)
• Quarantine and isolation (CDC)
• Molnupiravir in non-hospitalized patients (NEJM)
• Convalescent serum for outpatients (medRxiv)
• Letters read on TWiV 845
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkee

Send your questions for Dr. Griffin to [email protected]